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For many years, the contact lens field had focused on safetyassociated with contact lens wear—and for good reason,
given the lack of understanding of the risk factors and etiology
of serious complications such as microbial keratitis. However,
as knowledge came to light on these complications through the
1980s and 1990s, it allowed for practitioners to become more
comfortable managing these complications, along with the
introduction of products that helped reduce or prevent some of
these problems. It was during this time, beginning in the mid-
1980s, that the field itself became cognizant of the issues
associated with comfort, or discomfort, during contact lens
wear.
Since that time, we have witnessed the field (and industry)
shift its attention toward understanding the issue of contact
lens discomfort (CLD). Contact lens discomfort is a substan-
tial and burdensome problem experienced frequently by
contact lens wearers. It is well established that most contact
lens wearers experience CLD, at least occasionally, although
many experience CLD to such a severity that they feel
compelled to alter their wearing habits. Common, although
palliative at best, treatments include the periodic use of
rewetting drops, contact lens removal, contact lens refitting
(using different lens designs or materials or replacement
schedules), and changes in the contact lens care solutions or
regimens, in addition to other less commonly used approach-
es including topical or systemic medications, alterations in
diet, and punctal plugs. Ultimately, CLD is the primary factor
associated with permanent discontinuation from contact lens
wear.
Given the importance of the issue of CLD to both patients
and practitioners alike, the time was right to move the field
forward by taking steps to bring global consensus to our
current understanding of this condition.
PURPOSE AND OBJECTIVES
In recognition of this need, and after discussions with
international experts (i.e., Jennifer Craig, Gary Foulks, Lyndon
Jones, Eric Papas, Jason Nichols, Kelly Nichols, Fiona Stapleton,
and Mark Willcox) in January 2012, David Sullivan, president of
the Tear Film & Ocular Surface Society (TFOS), recommended
to the TFOS governing board that TFOS sponsor a workshop on
CLD. The goal would be to build a global consensus concerning
CLD using an evidence-based approach. The TFOS governing
board agreed. TFOS raised funds from industry to support this
initiative, invited individuals to serve on a steering committee,
and asked this committee to establish detailed objectives,
project a timeline, and select additional workshop participants.
TFOS also selected Investigative Ophthalmology and Visual
Science (IOVS) to publish the CLD Workshop report after
consultation with members of the governing board and steering
committee.
PROCESS
Organization
A steering committee was formed in February 2012 and met in
June 2012 in San Diego, California. The membership of the
steering committee can be found in Table 1.
The steering committee was charged with several tasks, and
the CLD Workshop was modeled after two prior workshops,
both sponsored by TFOS: the Dry Eye Workshop (DEWS;
provided in the public domain by TFOS at http://www.tearfilm.
org/tearfilm-reports-dews-report.php) and the Meibomian
Gland Dysfunction (MGD; provided in the public domain by
TFOS at http://www.tearfilm.org/tearfilm-reports-mgdreport.
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php) Workshop. The first charge of the steering committee
was to develop the CLD Workshop’s mission, including a series
of critical content areas and aims and objectives for workshop
focus. These were developed by the steering committee as
they were seen as key areas that would serve as the thematic
foundation for the workshop in terms of their importance in
characterizing CLD. The mission of the CLD Workshop was as
follows:
1. Conduct an evidence-based evaluation of CLD in health
and disease;
2. Develop a contemporary understanding of the defini-
tion, classification, epidemiology, and neurobiology of
CLD;
3. Examine the role of lens materials, design, and care in
the etiology of CLD;
4. Assess the biocompatibility of contact lenses with the
tear film and ocular surface;
5. Develop appropriate norms of trial design, including
outcome measures for CLD;
6. Develop recommendations for the management and
therapy of CLD; and
7. Develop recommendations for future innovative re-
search in CLD.
Following the creation of the CLD Workshop’s mission, a
second charge of the steering committee was the formation of
nine specific subcommittees, including their membership. In
total, 79 international experts were assembled to develop and
achieve consensus on CLD using an evidence-based approach.
The steering committee also appointed subcommittee chairs
and steering committee liaisons to each subcommittee. The
subcommittees and their membership can be found in Table 2.
Workshop Process
The CLD Workshop spanned an approximate 18-month period
from beginning to end, and included a series of meetings and
open presentations of the various subcommittees on the
approach and content. Once each subcommittee was formed
and members accepted their invitation for involvement, each
of the eight subcommittees (Table 2) met for a one- to one- and
a half-day in-person meeting in September and October 2012 in
various locations across the world in order to develop draft
subcommittee report outlines. The subcommittee outlines
were intended to document the scope and aims of each
subcommittee and were to be developed in draft form by each
subcommittee. Following the subcommittee meetings, each
subcommittee submitted a draft outline to the entire workshop
for review and content by mid-October 2012. Following an
open period of comment, the steering committee reviewed
and edited each outline, followed by approval of each outline
and return of a final outline to the various subcommittees. The
steering committee was charged with oversight of all
TABLE 1. TFOS CLD Workshop Steering Committee Organization
Chair: Jason J. Nichols (United States)
Vice chair: Mark Willcox (Australia)
Organizer: David A. Sullivan (United States)
Members: Joseph Ciolino (United States), Jennifer Craig (New
Zealand), Gary Foulks (United States), Lyndon Jones (Canada),
Kelly K. Nichols (United States), Christine Purslow (United
Kingdom), Fiona Stapleton (Australia)
Consultants: Anthony Bron (United Kingdom), Carlos Belmonte
(Spain), Murat Dogru (Japan), James F. Saviola (United States), Debra
A. Schaumberg (United States)
Operations manager: Rose M. Sullivan (United States)
TABLE 2. Subcommittees and Membership
Subcommittee Name Membership
Definition and
Classification
Kelly K. Nichols, chair and subcommittee
(SC) liaison (United States)
Desmond Fonn (Canada)
Lance Forstot (United States)
Brien Holden (Australia)
Jing-Feng Huang (United States)
Jean Jacob (United States)
J. Daniel Nelson (United States)
Rachel Redfern (United States)
Epidemiology Kathy Dumbleton, chair (Canada)
Christine Purslow, SC liaison (United
Kingdom)
Murat Dogru, consultant (Japan)
Barbara Caffery (Canada)
Sheila Hickson-Curran (United States)
Jami Kern (United States)
Takashi Kojima (Japan)
Philip Morgan (United Kingdom)
Danielle Robertson (United States)
Contact Lens Materials,
Design & Care
Lyndon Jones, chair and SC liaison
(Canada)
Noel Brennan (United States)
Jose Manuel Gonzalez-Meijome (Portugal)
John Lally (United States)
Carole Moldonada-Codina (United
Kingdom)
Tannin Schmidt (Canada)
Lakshman Subbaraman (Canada)
Graeme Young (United Kingdom)
Neurobiology of
Discomfort and Pain
Fiona Stapleton, co-chair and SC liaison
(Australia)
Mark Rosenblatt, co-chair (United States)
Carlos Belmonte, consultant (Spain)
Carolyn Begley (United States)
David Bereiter (United States)
Darlene Dartt (United States)
Juana Gallar (Spain)
Blanka Golebiowski (Australia)
Pedram Hamrah (United States)
Carl Marfurt (United States)
Contact Lens Interactions
with the Ocular Surface
& Adnexa
Nathan Efron, chair (Australia)
Jason J. Nichols, co-SC liaison
(United States)
Mark Willcox, co-SC liaison (Australia)
Anthony Bron, consultant (United
Kingdom)
Reiko Arita (Japan)
Stefano Barabino (Italy)
Erich Knop (Germany)
Maria Markoulli (Australia)
Alison McDermott (United States)
Edoardo Villani (Italy)
Contact Lens Interactions
with the Tear Film
Jennifer Craig, chair and SC liaison
(New Zealand)
Pablo Argu¨eso (United States)
Cecile Maissa (United Kingdom)
Ulrike Stahl (Canada)
Alan Tomlinson (United Kingdom)
Jay Wang (United States)
Mark Willcox (Australia)
Norihiko Yokoi (Japan)
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subcommittee outlines to ensure that the outlines were broad
in scope yet not overly redundant with one another.
Following steering committee approval of the final outlines,
the subcommittees were charged with developing a draft
version of the subcommittee report (based on the content
outline). Again, these reports were intended to be evidence
based, using the American Academy of Ophthalmology’s
Preferred Practice Pattern guidelines for levels of evidence.
By steering committee directive, the subcommittees were
primarily asked to focus on peer-reviewed literature, but could
include non–peer-reviewed literature in their reports when
needed (e.g., when there was no peer-reviewed literature).
Subcommittee representatives reviewed their progress at a
meeting of the Industry Liaison Subcommittee (ILS) in
Houston, Texas, in January 2013. The role of the ILS was to
provide proactive and reactive comments about the goals of,
and draft reports from, all other subcommittees. Toward that
end, ILS members forwarded their constructive critiques to
specific subcommittees for their consideration. In this way the
workshop process was able to benefit from the collective
experience and knowledge of all industry sponsors.
Subcommittee draft reports were due to the steering
committee by April 1, 2013, in anticipation of a post-
Association for Research in Vision and Ophthalmology (ARVO)
TFOS CLD Workshop plenary session (May 10–11, 2013,
Seattle, WA). All subcommittee report drafts were openly
circulated prior to the post-ARVO meeting to the entire CLD
Workshop for review.
At the post-ARVO plenary session, the eight subcommittee
chairs presented the draft version of their subcommittee
reports to all members of the CLD Workshop in attendance
(the entire CLD Workshop membership). This was an open
period for further comments, suggestions, dialogue, develop-
ment, and refinement of the draft reports. Each subcommittee
was then tasked with refining their draft reports and
submitting them to the steering committee by June 1, 2013.
Following submission of the draft reports to the steering
committee, the reports were assigned to the Harmonization
Subcommittee appointed by the steering committee, the
membership of which can be found in Table 3. The goals of
the Harmonization Subcommittee were to review, edit, and
develop the subcommittee draft reports to ensure that all
content included was evidence based and that the content was
expansive and broad in scope. Further, the Harmonization
Subcommittee was tasked by review of all of the eight
subcommittee reports to have a global overview of the content
of each, also ensuring that each report was focused on its
outlines and on removing redundancies.
The subcommittee report harmonization period lasted
through September 2013, and once each report was taken
through the harmonization process and finalized, the final
version was returned to the subcommittee for their review.
Lastly, the reports were submitted to IOVS prior to the TFOS
Seventh International Conference on the Tear Film & Ocular
Surface: Basic Science and Clinical Relevance (Taormina, Sicily,
September 18–21, 2013). During this conference, the CLD
Workshop reports were presented to the public for the very
first time.
FUTURE DIRECTIONS
While the details of the subcommittee reports and findings are
found within the pages of this journal, it is important to
recognize that it became apparent to many involved in the
workshop process that ‘‘we just don’t know as much as we
thought we knew’’ about CLD. While there are hundreds, even
perhaps thousands, of scientific papers that may relate to CLD
in some way, it is clear that there are still significant gaps in our
knowledge about this condition.
While it is obvious that CLD is a condition associated with
the wearing of contact lenses, the condition remains equivocal
in many senses. Below are key areas that need further study,
delineation, and characterization, broken down by subcom-
mittee.
Definition and Classification
1. Relative to classifying CLD, is it appropriate to differen-
tiate CLD as distinct from dry eye disease, given the
significant overlap of phenotypic characteristics of the
two conditions?
2. Are there better ways to classify CLD, rather than
focusing on contact lens and patient attributes?
Epidemiology
1. What is the natural history of CLD? What is the average
age of onset, and how long do patients live with CLD
prior to dropping out of contact lenses?
TABLE 2. Continued
Subcommittee Name Membership
Trial Design & Outcomes Gary Foulks, chair and SC liaison (United
States)
James F. Saviola, consultant (United
States)
Debra A. Schaumberg, consultant (United
States)
Robin Chalmers (United States)
William Gleason (United States)
Isabelle Jalbert (Australia)
Nancy Keir (Canada)
Richard E. Lippman (United States)
Trefford Simpson (Canada)
Craig Woods (Australia)
Management & Therapy Eric Papas, chair (Australia)
Joseph Ciolino, SC liaison (United States)
Deborah Jacobs (United States)
William Miller (United States)
Heiko Pult (Germany)
Afsun Sahin (Turkey)
Sruthi Srinivasan (Canada)
Joseph Tauber (United States)
James Wolffsohn (United Kingdom)
Industry Liaison David A. Sullivan, chair and SC liaison
(United States)
Jean-Fre´de´ric Chibret (Laboratoires The´a)
Haruyuki Hiratani (Menicon)
Carol Lakkis (Vistakon)
Haixia Liu (Allergan)
Mohinder Merchea (Bausch & Lomb)
Masatsugu Nakamura (Santen)
Robert Scott (Alcon)
TABLE 3. TFOS CLD Workshop Harmonization Subcommittee
Chair: Jason J. Nichols (United States)
Vice chair: Mark Willcox (Australia)
Members: Lyndon Jones (Canada), J. Daniel Nelson (United States),
Fiona Stapleton (Australia)
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2. What are the risk factors for CLD?
3. Should CLD be considered distinct from other forms of
dry eye disease (e.g., MGD) when the epidemiology of
dry eye disease is evaluated?
Materials, Design, and Care
1. What contact lens material attributes have the most
influence on CLD?
2. Are there advanced technologies in lens design that
could reduce CLD?
3. What specific components in contact lens care systems
matter most in improving comfort during CL wear? Are
there specific steps in the regimen that matter more
than others in terms of comfort?
4. How significant is replacement frequency in improving
CLD? Are there substantially meaningful differences
between lenses replaced daily, every two weeks, and
monthly in preventing patients from reducing or
discontinuing contact lens wear?
Neurobiology of Discomfort
1. What models can be used to determine the exact
sensory pathways in CLD? Do sensory changes to the
conjunctiva occur as a result of neural adaptation due to
the continued stimulus of a contact lens, and how do
those sensory changes mediate discomfort?
2. Does neural sensitization due to hyperosmolarity or
inflammatory mediators in the tears contribute to CLD?
3. What corneal mediators, or neuropeptides, are altered
during contact lens wear that interplay with the
neurobiological system?
4. Is the key interaction related to CLD the upper lid (lid
wiper zone) with the contact lens, and what role does
sensing cooling effects have in CLD?
Ocular Surface and Adnexa
1. Is meibomian gland loss or atrophy in contact lens
wearers the initial cascade that leads to other tissue
changes provoking symptoms of discomfort?
2. How can contact lenses and care solutions be better
improved to increase biocompatibility during lens
wear?
3. Are changes to the ocular surface, such as corneal
and conjunctival staining or changes in goblet cell
density, more important in CLD than we presently
realize?
Tear Film
1. Relative to the altered lipid layer and increased
evaporation during contact lens wear, can the actual
class, or species, of lipid that is associated with these
changes be determined?
2. Are proteins from the ocular surface released into the
tear film that change the stabilization of the tears during
contact lens wear, leading to structural alterations of the
tear film?
3. What role is there for mucin degradation during contact
lens wear in CLD?
4. Is it possible to better elucidate how the ‘‘compart-
ments’’ of the pre- and postlens tear film found during
contact lens wear impact on CLD in a relative sense, if at
all?
Trial Design and Outcomes
1. How will the definition of CLD as determined in this
workshop report be adopted in clinical trial research?
2. Can trial design be better standardized and can validated
endpoints be agreed upon?
3. Is it possible to determine specific objective outcomes,
or even biomarkers, that predict symptoms reported by
patients with CLD?
Management and Therapy
1. It is well recognized that most management strategies
and therapies used in managing CLD are not entirely
effective. What investments are needed to move the
field forward to advance clinical care of these patients?
2. How can future knowledge of the impact of various
contact lens materials and care solution attributes be
harnessed into improving the care of the patient with
CLD?
3. Are pharmaceutical agents or devices alone, or in
combination with contact lenses, able to improve CLD
in order to prolong safe and comfortable wear of contact
lenses?
CONCLUSIONS
The TFOS International Workshop on Contact Lens Discomfort
was an 18-month process of open communication, dialogue,
and transparency among workshop participants that culminat-
ed in a series of evidence-based reports. These eight reports are
the work and dedication of 79 global experts, and are the
consensus-based efforts that define the current state of CLD, a
condition characterized by episodic or persistent adverse
ocular sensations that can ultimately lead to decreased wearing
time or discontinuation of contact lens wear. It is the aspiration
of those involved in the CLD Workshop that these reports serve
as a blueprint for future research and clinical activity such that
CLD can be reduced or eliminated, leading to successful long-
term wear of contact lenses for millions of people across the
world.
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